a year ago

Pathios Therapeutics Secures €23.4 Million to Advance Novel Cancer Immunotherapy

  • UK-based biotech company Pathios Therapeutics has raised €23.4 million in a Series B funding round

  • The round was led by Bristol Myers Squibb, with participation from existing investors Canaan and Brandon Capital

  • The funding will support the development of Pathios' first-in-class cancer immunotherapy approach, which targets GPR65, a novel target associated with immune-mediated diseases

  • The company plans to advance its lead candidate, PTT-4256, into clinical trials for advanced solid cancers by the end of 2024.

      • ProblemLife Sciences

      "making it difficult for the immune system to kill cancer cells by creating an acidic environment for the cancer cells to thrive"

      Solution

      "blocking the acid sensing receptor GPR65 to counteract the immunosuppressive polarization of immune cells, allowing the immune system to kill cancer cells effectively"

      Covered on